login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ATYR PHARMA INC (LIFE) Stock News
USA
- NASDAQ:LIFE -
US0021202025
-
Common Stock
1.9
USD
+0.05 (+2.7%)
Last: 6/4/2024, 8:12:25 PM
1.94
USD
+0.04 (+2.11%)
After Hours:
6/4/2024, 8:12:25 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
LIFE Latest News, Press Relases and Analysis
All
Press Releases
13 days ago - By: Bloomberg
Most US IPOs Remain Stuck In Limbo Despite SEC’s Shutdown Fix
a month ago - By: Ethos Technologies Inc
Ethos Files Registration Statement for Proposed Initial Public Offering
a month ago - By: Ethos Technologies Inc
Ethos Files Registration Statement for Proposed Initial Public Offering
2 months ago - By: The Motley Fool
- Mentions:
MLTX
2 Small-Cap Biotech Stocks Well Positioned for a Breakout
1 years ago - By: BusinessInsider
LIFE Stock Earnings: aTyr Pharma Beats EPS, Beats Revenue for Q1 2024
2 years ago - By: aTyr Pharma, Inc.
aTyr Pharma to Participate in April Investor Conferences
2 years ago - By: BusinessInsider
LIFE Stock Earnings: aTyr Pharma Misses EPS for Q4 2023
2 years ago - By: InvestorPlace
LIFE Stock Earnings: aTyr Pharma Misses EPS for Q4 2023
2 months ago - By: Ethos Technologies Inc
Ethos and Lifeforce Team Up to Help Policyholders Live Longer, Healthier Lives
3 months ago - By: The Motley Fool
- Mentions:
ZETA
CRM
EVTL
MSFT
...
3 Innovation Stocks With Parabolic Upside Potential
3 months ago - By: Ethos Technologies Inc
Insurtech Leader Ethos Adds Industry Veteran William Wheeler to Board of Directors
2 years ago - By: Benzinga
Recap: aTyr Pharma Q4 Earnings
2 years ago - By: Benzinga
aTyr Pharma's Earnings Outlook
2 years ago - By: InvestorPlace
- Mentions:
PTN
VERU
The 3 Best Penny Stocks to Buy in February 2024
3 months ago - By: Ethos Technologies Inc
- Mentions:
EVR
Insurtech Leader Ethos Adds Industry Veteran William Wheeler to Board of Directors
a year ago - By: InvestorPlace
- Mentions:
RELI
BLRX
KCSP
ADIL
...
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
a year ago - By: aTyr Pharma, Inc.
- Mentions:
ATYR
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
a year ago - By: aTyr Pharma, Inc.
- Mentions:
ATYR
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
a year ago - By: aTyr Pharma, Inc.
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
a year ago - By: aTyr Pharma, Inc.
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
a year ago - By: aTyr Pharma, Inc.
aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
a year ago - By: aTyr Pharma, Inc.
aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
a year ago - By: aTyr Pharma, Inc.
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
a year ago - By: aTyr Pharma, Inc.
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
a year ago - By: aTyr Pharma, Inc.
aTyr Pharma to Present at Upcoming Investor Conferences
1 years ago - By: InvestorPlace
LIFE Stock Earnings: aTyr Pharma Beats EPS, Beats Revenue for Q1 2024
1 years ago - By: aTyr Pharma, Inc.
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
1 years ago - By: aTyr Pharma, Inc.
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
2 years ago - By: aTyr Pharma, Inc.
aTyr Pharma to Participate in April Investor Conferences
2 years ago - By: InvestorPlace
- Mentions:
CLNN
CYBN
3 Penny Stocks That Could Be Multibaggers in the Making: March Edition
2 years ago - By: aTyr Pharma, Inc.
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
2 years ago - By: aTyr Pharma, Inc.
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
2 years ago - By: aTyr Pharma, Inc.
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
2 years ago - By: aTyr Pharma, Inc.
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
2 years ago - By: aTyr Pharma, Inc.
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
2 years ago - By: aTyr Pharma, Inc.
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
2 years ago - By: aTyr Pharma, Inc.
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
Please enable JavaScript to continue using this application.